ESMO Congress | Conference

Frontline VR-CAP Is Effective and Well Tolerated in MZL

October 23rd 2023

Bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride generated robust responses with a tolerable safety profile when delivered as first-line therapy in patients with marginal zone lymphoma.

Frontline Sobuzoxane Plus Etoposide and Rituximab is Safe and Effective in Older DLBCL Population

October 23rd 2023

The combination of sobuzoxane and etoposide plus rituximab prolonged survival and showcased a tolerable safety profile in patients with previously untreated diffuse large B-cell lymphoma aged 80 years and older.

Frontline Amivantamab Plus Lazertinib Bests Osimertinib in Advanced EGFR+ NSCLC

October 23rd 2023

The combination of amivantamab and lazertinib reduced the risk of disease progression or death by 30% compared with osimertinib alone as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

mRNA-4157 Plus Pembrolizumab Bolsters RFS in Resected Melanoma

October 23rd 2023

The addition of mRNA-4157 to pembrolizumab led to clinically significant improvements in relapse-free survival and distant metastasis–free survival vs pembrolizumab alone in patients with high-risk resected melanoma.

Lenvatinib/Pembrolizumab/Chemo Is Safe With Early Efficacy Signals in mESCC

October 23rd 2023

The combination of lenvatinib, pembrolizumab, and chemotherapy had a manageable safety profile and elicited preliminary antitumor activity in patients with metastatic esophageal squamous cell carcinoma.

Exploratory Analysis Shows Continued Lenvatinib After Pembrolizumab/Lenvatinab Provides Clinical Benefit in Previously Treated Endometrial Cancer

October 23rd 2023

Continued treatment with lenvatinib monotherapy after the completeion of combination therapy with pembrolizumab and lenvatinib resulted in sustained clinical benefit vs chemotherapy alone in patients with previously treated advanced endometrial cancer.

Lutetium Lu 177 Vipivotide Tetraxetan Boosts rPFS in Taxane-Naïve mCRPC After Prior AR Inhibitor

October 23rd 2023

Treatment with lutetium Lu 177 vipivotide tetraxetran improved radiographic progression-free survival compared with abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer who were taxane naïve and experienced disease progression on a prior second-generation androgen receptor pathway inhibitor.

Novel Bispecific Antibody EX103 Demonstrates Safety, Elicits Preliminary Antitumor Activity in R/R B-Cell NHL

October 23rd 2023

The novel CD20xCD3 bispecific antibody EX103 displayed a favorable safety profile and produced preliminary antitumor activity in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dato-DXd Provides PFS Benefit in HR+/HER2– Breast Cancer

October 23rd 2023

Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy for patients with hormone receptor-positive, HER2-low or -negative, metastatic breast cancer.

Lenvatinib/Pembrolizumab Combo Elicits Durable Responses in Advanced ccRCC

October 23rd 2023

Lenvatinib in combination with pembrolizumab led to tumor shrinkage and duration of response benefits compared with sunitinib across subgroups of interest in patients with advanced clear cell renal cell carcinoma.

Dr Cho on First-Line Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC

October 23rd 2023

Byoung Chul Cho, MD, PhD, discusses key findings from the phase 3 MARIPOSA study of first-line amivantamab plus lazertinib vs osimertinib in EGFR-mutant locally advanced or metastatic non– small cell lung cancer.

Subgroup Analysis Shows Dostarlimab/Chemotherapy Elicits PFS Benefit in dMMR/MSI-H, TP53+, and NSMP Endometrial Cancer

October 23rd 2023

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial Carcinoma

October 22nd 2023

Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors

October 22nd 2023

Patients with advanced neuroendocrine tumors who experienced progression following prior therapy experienced a significant improvement in terms of progression-free survival after treatment with cabozantinib compared with placebo.

Sotorasib Plus Panitumumab Extends PFS in Refractory KRAS G12C+ mCRC

October 22nd 2023

Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

Induction Chemotherapy Prior to Chemoradiation Represents Potential New SOC in Locally Advanced Cervical Cancer

October 22nd 2023

Treatment with platinum-based chemotherapy prior to the administration of chemoradiation led to statistically significant improvements in progression-free survival and overall survival compared with chemoradiation alone in patients with locally advanced cervical cancer.

Tisotumab Vedotin Improves Survival in Recurrent/Metastatic Cervical Cancer

October 22nd 2023

Tisotumab vedotin led to a 30% reduction in the risk of death vs investigator’s choice of chemotherapy as second- or third-line therapy in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

Trastuzumab Deruxtecan Has Clinically Meaningful Activity in Solid Tumors Harboring HER2 Mutations

October 22nd 2023

Fam-trastuzumab deruxtecan-nxki elicited responses that proved to be durable in patients with a range of solid tumors harboring HER2 mutations.

Dr Pietrantonio on the CodeBreak 300 Trial in KRAS G12C-mutated mCRC

October 22nd 2023

Filippo Pietrantonio, MD, discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

Dr Chi on the MAGNITUDE Trial of Niraparib Plus Abiraterone in BRCA-Mutated mCRPC

October 22nd 2023

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.